Related Experiment Video
Updated: May 16, 2026

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
Published on: April 23, 2021
Association between interleukin-6 levels and first-ever cerebrovascular events in patients with vascular risk factors
Kaori Miwa1, Makiko Tanaka, Shuhei Okazaki
1Department of Neurology and Stroke Center, Osaka University Graduate School of Medicine, Osaka, Japan.
Insights
Interleukin-6 (IL-6) is linked to cerebrovascular events (CVEs) risk. Combining IL-6 with silent lacunar infarction (SLI) improves risk prediction in patients with vascular risk factors.
Area of Science:
- Cardiology
- Neurology
- Inflammation Research
Background:
- Cerebrovascular events (CVEs) pose a significant health burden.
- Subclinical vascular disease and inflammatory markers are implicated in CVEs.
- Early identification of individuals at high risk is crucial for prevention.
Purpose of the Study:
- To investigate the association between inflammatory markers and the risk of first-ever CVEs.
- To evaluate the role of subclinical vascular disease in this association.
- To assess the predictive value of inflammatory markers and subclinical disease for CVEs.
Main Methods:
- 464 outpatients with vascular risk factors but no prior cardiovascular disease were enrolled.
- Subclinical vascular disease was assessed using MRI for silent lacunar infarction (SLI) and ultrasound for carotid intima-media thickness.
- High-sensitivity C-reactive protein, interleukin (IL)-6, and IL-18 were measured.
- Cox proportional hazards models were used to assess associations with CVEs over a 4.8-year follow-up.
Main Results:
- Interleukin-6 (IL-6) was significantly associated with CVEs risk, independent of high-sensitivity C-reactive protein and IL-18.
- The association of IL-6 with CVEs remained significant after adjusting for conventional risk factors, carotid intima-media thickness, and SLI.
- Patients with both elevated IL-6 and SLI exhibited a substantially higher risk of CVEs compared to those with neither.
- The combination of IL-6 and SLI improved risk reclassification and discrimination for CVEs.
Conclusions:
- Interleukin-6 (IL-6) is an independent predictor of cerebrovascular events (CVEs).
- IL-6 levels, particularly in conjunction with silent lacunar infarction (SLI), enhance the prediction of CVE risk.
- These findings suggest IL-6 and SLI can be valuable biomarkers for identifying high-risk individuals for CVE prevention strategies.
Objective:
The objective of this study was to examine the association of inflammatory markers with risk of first-ever cerebrovascular events (CVEs), while simultaneously evaluating subclinical vascular disease.
Methods And Results:
We enrolled 464 outpatients who had vascular risk factors without any preexisting cardiovascular disease. We examined the presence of silent lacunar infarction (SLI) by magnetic resonance imaging; carotid intima-media thickness by ultrasound; and measured high-sensitivity C-reactive protein, interleukin (IL)-6, and IL-18 at baseline, and assessed their associations with CVEs using Cox proportional hazards models of 4.8±2.6 years follow-up. We further calculated measures of reclassification and discrimination. In age- and sex-adjusted analysis, IL-6, but neither high-sensitivity C-reactive protein nor IL-18, was associated with CVEs. The association remained significant after adjustment for conventional risk factors, intima-media thickness, and SLI (hazard ratios: 1.80, per 1-SD increase in log IL-6, P=0.03). Compared with the patients with below median IL-6 without SLI, those with above median IL-6 and SLI had a higher risk of CVEs (hazard ratios: 4.14, P=0.0014). The combination of IL-6 and SLI resulted in the net reclassification improvement of 14.3% (P=0.04), and the integrated discrimination improvement gain of 2.1% (P=0.05).
Conclusions:
IL-6 levels were independently associated with CVEs and could improve reclassification in those with SLI.
More Related Videos
08:51Application of Unsupervised Multi-Omic Factor Analysis to Uncover Patterns of Variation and Molecular Processes Linked to Cardiovascular Disease
Published on: September 20, 2024
06:29Accurate and Simple Measurement of the Pro-inflammatory Cytokine IL-1β using a Whole Blood Stimulation Assay
Published on: March 1, 2011
Related Concept Videos
Ischemic Stroke ll: Pathophysiology
Ischemic Stroke l: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Hemorrhagic Stroke ll: Pathophysiology
Cerebral Edema ll: Pathophysiology
Venous Thrombosis I: Introduction